34/120
1.4 / 5 stars
All 120 Win/Lose results shown below
PBYI Roast Me summary
PUMA BIOTECHNOLOGY, INC. (PBYI). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinPBYI / S&P 26.92% / 15.20% |
LosePBYI / S&P -2.86% / 15.00% |
LosePBYI / S&P -47.47% / 50.40% |
| 2026-Q11/3 |
WinPBYI / S&P 7.39% / -4.33% |
LosePBYI / S&P -2.38% / 11.30% |
LosePBYI / S&P -38.46% / 27.70% |
| 2025-Q41/3 |
WinPBYI / S&P 12.05% / 2.65% |
LosePBYI / S&P -0.91% / 9.00% |
LosePBYI / S&P -1.61% / 13.40% |
| 2025-Q32/3 |
WinPBYI / S&P 54.81% / 8.12% |
LosePBYI / S&P -12.96% / 4.61% |
WinPBYI / S&P 59.57% / 13.45% |
| 2025-Q23/3 |
WinPBYI / S&P 15.88% / 10.94% |
WinPBYI / S&P 8.63% / 4.83% |
WinPBYI / S&P 450.00% / 10.63% |
| 2025-Q12/3 |
WinPBYI / S&P -2.95% / -4.27% |
LosePBYI / S&P 2.68% / 4.98% |
WinPBYI / S&P 143.75% / 10.57% |
| 2024-Q42/3 |
WinPBYI / S&P 19.61% / 2.41% |
LosePBYI / S&P -2.19% / 5.25% |
WinPBYI / S&P 37.78% / 6.15% |
| 2024-Q32/3 |
LosePBYI / S&P -21.78% / 5.89% |
WinPBYI / S&P 6.30% / 5.89% |
WinPBYI / S&P 571.43% / 6.11% |
| 2024-Q20/3 |
LosePBYI / S&P -38.49% / 4.28% |
LosePBYI / S&P -4.77% / 5.38% |
LosePBYI / S&P PBYI unavailable / 5.12% |
| 2024-Q12/3 |
WinPBYI / S&P 22.40% / 10.56% |
LosePBYI / S&P -3.59% / 5.71% |
WinPBYI / S&P 220.00% / 5.59% |
| 2023-Q41/3 |
WinPBYI / S&P 64.64% / 11.69% |
LosePBYI / S&P 3.34% / 6.81% |
LosePBYI / S&P PBYI unavailable / 7.78% |
| 2023-Q30/3 |
LosePBYI / S&P -25.50% / -3.27% |
LosePBYI / S&P 5.25% / 7.52% |
LosePBYI / S&P -68.18% / -5.03% |
| 2023-Q22/3 |
WinPBYI / S&P 14.24% / 8.74% |
WinPBYI / S&P 11.25% / 9.50% |
LosePBYI / S&P PBYI unavailable / -8.57% |
| 2023-Q11/3 |
LosePBYI / S&P -26.95% / 7.50% |
WinPBYI / S&P 17.11% / 10.77% |
LosePBYI / S&P PBYI unavailable / -15.69% |
| 2022-Q41/3 |
WinPBYI / S&P 78.48% / 7.56% |
LosePBYI / S&P -9.92% / 11.88% |
LosePBYI / S&P PBYI unavailable / -17.99% |
| 2022-Q30/3 |
LosePBYI / S&P -16.84% / -4.88% |
LosePBYI / S&P -13.04% / 13.47% |
LosePBYI / S&P PBYI unavailable / -1.41% |
| 2022-Q21/3 |
WinPBYI / S&P -1.04% / -16.10% |
LosePBYI / S&P -18.84% / 13.71% |
LosePBYI / S&P PBYI unavailable / 11.04% |
| 2022-Q10/3 |
LosePBYI / S&P -5.26% / -4.60% |
LosePBYI / S&P -26.22% / 15.97% |
LosePBYI / S&P PBYI unavailable / 42.23% |
| 2021-Q40/3 |
LosePBYI / S&P -56.63% / 11.03% |
LosePBYI / S&P 12.46% / 15.00% |
LosePBYI / S&P PBYI unavailable / 96.40% |
| 2021-Q30/3 |
LosePBYI / S&P -23.64% / 0.58% |
LosePBYI / S&P 6.32% / 10.77% |
LosePBYI / S&P PBYI unavailable / 69.42% |
| 2021-Q20/3 |
LosePBYI / S&P -5.56% / 8.55% |
LosePBYI / S&P 5.72% / 6.58% |
LosePBYI / S&P PBYI unavailable / 51.81% |
| 2021-Q11/3 |
LosePBYI / S&P -5.26% / 6.17% |
WinPBYI / S&P 21.23% / -1.06% |
LosePBYI / S&P PBYI unavailable / 7.39% |
| 2020-Q40/3 |
LosePBYI / S&P 1.68% / 12.15% |
LosePBYI / S&P -17.32% / -3.72% |
LosePBYI / S&P PBYI unavailable / -33.42% |
| 2020-Q30/3 |
LosePBYI / S&P -3.26% / 8.93% |
LosePBYI / S&P -16.03% / -2.04% |
LosePBYI / S&P PBYI unavailable / -27.10% |
| 2020-Q21/3 |
WinPBYI / S&P 23.58% / 20.54% |
LosePBYI / S&P -15.91% / -0.46% |
LosePBYI / S&P PBYI unavailable / -27.11% |
| 2020-Q11/3 |
WinPBYI / S&P -3.54% / -19.60% |
LosePBYI / S&P -20.85% / 3.47% |
LosePBYI / S&P PBYI unavailable / -14.75% |
| 2019-Q41/3 |
LosePBYI / S&P -18.76% / 9.07% |
WinPBYI / S&P 8.47% / 5.36% |
LosePBYI / S&P PBYI unavailable / 2.99% |
| 2019-Q31/3 |
LosePBYI / S&P -15.26% / 1.70% |
WinPBYI / S&P 39.15% / 5.02% |
LosePBYI / S&P PBYI unavailable / 0.21% |
| 2019-Q21/3 |
LosePBYI / S&P -67.23% / 4.30% |
WinPBYI / S&P 97.76% / 6.64% |
LosePBYI / S&P PBYI unavailable / 8.65% |
| 2019-Q11/3 |
WinPBYI / S&P 90.61% / 13.65% |
LosePBYI / S&P PBYI unavailable / 8.12% |
LosePBYI / S&P PBYI unavailable / 14.29% |
| 2018-Q41/3 |
LosePBYI / S&P -55.62% / -13.52% |
WinPBYI / S&P 806.60% / 9.05% |
LosePBYI / S&P PBYI unavailable / 18.23% |
| 2018-Q30/3 |
LosePBYI / S&P -22.49% / 7.71% |
LosePBYI / S&P PBYI unavailable / 10.21% |
LosePBYI / S&P PBYI unavailable / 19.06% |
| 2018-Q20/3 |
LosePBYI / S&P -13.08% / 3.43% |
LosePBYI / S&P PBYI unavailable / 9.03% |
LosePBYI / S&P PBYI unavailable / 14.46% |
| 2018-Q10/3 |
LosePBYI / S&P -31.16% / -0.76% |
LosePBYI / S&P PBYI unavailable / 7.68% |
LosePBYI / S&P PBYI unavailable / 12.46% |
| 2017-Q40/3 |
LosePBYI / S&P -17.45% / 6.64% |
LosePBYI / S&P PBYI unavailable / 7.03% |
LosePBYI / S&P PBYI unavailable / 13.82% |
| 2017-Q31/3 |
WinPBYI / S&P 37.01% / 4.48% |
LosePBYI / S&P PBYI unavailable / 5.68% |
LosePBYI / S&P PBYI unavailable / 17.57% |
| 2017-Q21/3 |
WinPBYI / S&P 134.95% / 3.09% |
LosePBYI / S&P PBYI unavailable / 4.83% |
LosePBYI / S&P PBYI unavailable / 17.74% |
| 2017-Q11/3 |
WinPBYI / S&P 21.17% / 6.07% |
LosePBYI / S&P PBYI unavailable / 3.67% |
LosePBYI / S&P PBYI unavailable / 13.32% |
| 2016-Q40/3 |
LosePBYI / S&P -54.21% / 3.82% |
LosePBYI / S&P PBYI unavailable / 2.09% |
LosePBYI / S&P PBYI unavailable / 7.05% |
| 2016-Q31/3 |
WinPBYI / S&P 125.08% / 3.85% |
LosePBYI / S&P PBYI unavailable / 0.20% |
LosePBYI / S&P PBYI unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | PBYI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 79.86% | 20.78% |
| Annualized return | 79.86% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | PBYI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 19.91% | 83.14% |
| Annualized return | 3.70% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | PBYI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -84.56% | 319.30% |
| Annualized return | -17.04% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |